Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676520 · ClinicalTrials.gov registry record
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 8,053
- Enrollment target
NCT00676520 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 8,053 participants.
The verdict
NCT00676520 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 8,053 participants
- Enrollment target
Study Summary
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are * To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and * To support the Food and Drug Administration (FDA) dual antiplatelet therapy (DAPT) initiative. This initiative is designed to evaluate the composite of all death, myocardial infarction (MI) and stroke (MACCE) and the survival of patients that are free from Academic Research Consortium (ARC) definite or probable stent thrombosis (ST) and that have been treated with drug eluting stents (DES) and extended dual antiplatelet therapy.
Interventions
- DEVICE XIENCE V® Everolimus Eluting Coronary Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,053 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00676520
The ClinicalTrials.gov registry entry for NCT00676520 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8,053 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XIENCE V® Everolimus Eluting Coronary Stent is the first listed.
NCT00676520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00676520 about?
NCT00676520 is a clinical study titled "XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)". XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are * To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and * To support the Food and Drug Administration (FDA) dual antiplatelet the...
What is the current status of trial NCT00676520?
This trial is currently completed. The enrollment target is 8,053 participants. The study started on 2008-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00676520?
The interventions under investigation include: XIENCE V® Everolimus Eluting Coronary Stent (DEVICE).
Who is sponsoring clinical trial NCT00676520?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.